Pedro Mendes‐Bastos

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2021 · 112 citations · Full text

Il-23 Inhibitors, Medicine, Drug Survival +6

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2022 · 73 citations · Full text

Inflammation, Drug Survival, Immunology +7

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

Amy S. Paller, Barry Ladizinski, Pedro Mendes‐Bastos et al. · JAMA Dermatology · 2023 · 56 citations · Full text

Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials

Pedro Mendes‐Bastos, Barry Ladizinski, Emma Guttman‐Yassky et al. · Journal of the American Academy of Dermatology · 2022 · 55 citations · Full text